INTRODUCTION
============

Asthma is a chronic inflammatory disease of multifactorial etiologies that affects 300 million people worldwide. Initially, asthma was considered typical eosinophilic airway inflammation initiated by allergic sensitization, which results in airway hyperresponsiveness (AHR) and acute bronchoconstriction. Among asthmatic patients, severe asthma (SA) is responsible for more than 50% of the medical expense of asthma, even though it accounts for 5%-10% of entire asthma patients. Severe asthmatics are suffering from frequent exacerbations that contribute to progressive lung function decline and increasing burden of medical cost.[@B1]

The eosinophilic phenotype of asthma is related to type 2 cytokines such as interleukin (IL)-4, IL-5, and IL-13. Corticosteroid (CS) is a key anti-inflammatory agent to control eosinophilic inflammation, and biologics targeting type 2 inflammation are effective in SA with high total eosinophil count (TEC).[@B2][@B3] There have been traditional biomarkers used to monitor eosinophilic inflammation in asthma, including TEC, sputum eosinophil count (%), serum periostin level, and fractional excretion of nitric oxide (FeNO) concentration.[@B4] Not only are sputum eosinophil count and FeNO concentration relatively hard to yield and variable by CS therapy, but also the studies of TEC predicting sputum eosinophil counts in eosinophilic asthma have shown conflicting results.[@B5][@B6][@B7][@B8][@B9][@B10] To date, TEC has been suggested to be a biomarker for predicting favorable responses to anti-IL-5 antibody treatment in SA.[@B11][@B12][@B13] Since there has been no serum biomarker available that can effectively reflect eosinophilic inflammation in SA, the need to identify an appropriate biomarker is continuously emerging. While periostin has been known to be related to type 2 airway inflammation in asthma, several studies have reported eosinophil-derived neurotoxin (EDN), a degranulation protein released from eosinophils, is deemed to represent eosinophil activation in childhood asthma and atopic dermatitis, and its value as a serum biomarker has not yet been evaluated in adult severe asthmatics.[@B14][@B15]

We hypothesized that serum EDN could predict SA. This study aimed to analyze the association of serum EDN with eosinophil-related clinical parameters, including TEC, and serum periostin level in patients with SA as compared to those with nonsevere asthma (NSA). It also aimed to validate the new enzyme-linked immunosorbent assay (ELISA) kit developed in this country.

MATERIALS AND METHODS
=====================

Study populations
-----------------

A total of 1,133 Korean adult asthmatic patients, including 898 severe and 235 nonsevere asthmatics, were enrolled in the study. The study populations included 125 normal controls (NCs) without known allergic diseases. Allergy specialists diagnosed asthma according to the Global Initiative for Asthma guideline. The subjects were classified into the SA and NSA groups by the International European Respiratory Society/American Thoracic Society guidelines.[@B16] Any patient who had known to have underlying respiratory diseases other than asthma was excluded. All participants provided written informed consent before participating in this study, and Ajou University Institutional Review Board approval was obtained (AJIRB-GEN-SMP-13-108).

The demographic characteristics of the study subjects were collected, including age, sex, smoking history, and the duration of asthma. Atopy was defined as at least 1 positive reaction to a skin prick test of 55 common inhalant allergens (Bencard Co., Brentford, UK), in which a positive reaction was defined as the ratio of the mean diameter of wheal of the allergen to histamine was 1 or higher. Chronic rhinosinusitis and nasal polyps were diagnosed with paranasal sinus radiography, computed tomography, and rhinoscopic findings. Pulmonary function test was completed as previously described.[@B17] Methacholine bronchial challenge test was performed using double doses of Provocholine^®^ (methacholine chloride USP, Methapharm Inc., Brantford, Canada) from 1 to 16 mg/mL. Serum total immunoglobulin E (IgE), serum specific IgE, and serum eosinophil cationic protein (ECP) levels were measured by the UniCAP^®^ system (ThermoFisher Scientific, Waltham, MA, USA). Serum samples were collected at the initial visit and frozen at −70°C; on initial evaluation, they were thawed immediately before use. Sputum eosinophil and neutrophil counts were expressed as the percentage of the cells among nonsquamous cells in the samples.

Measurement of serum EDN and serum periostin
--------------------------------------------

The serum levels of EDN were measured using 2 different ELISA kits, following each manufacturer\'s protocol. The one is a commercial kit that has already been used for the measurement of EDN (MBL International, Woburn, MA, USA), and the other is a newly developed kit named the K-EDN kit (SKIMS-BIO Co., Seoul, Korea). Their measurements were taken as previously described.[@B18] As another biomarker for eosinophilic inflammation, serum periostin levels were measured simultaneously using ELISA (Shino-Test, Kanagawa, Japan) as previously described.[@B19]

Statistical analysis
--------------------

The Mann-Whitney *U* test and the χ^2^ test were used to compare the unpaired continuous and dichotomous variables. Spearman rank correlation analysis defined correlations among the continuous variables. Logistic regression analyses identified the contributions of continuous and dichotomous variables to SA. All statistical analyses were performed by using IBM SPSS software version 18.0 (IBM Corp., Armonk, NY, USA). *P* values of \< 0.05 were considered statistically significant.

RESULTS
=======

Demographic and clinical characteristics
----------------------------------------

Demographic and clinical parameters of the study subjects were compared ([Table 1](#T1){ref-type="table"}). Severe asthmatics were older (46.01 ± 13.93 *vs.* 42.69 ± 14.63 years, *P* = 0.001) and had more frequent smoking history (57.4% *vs.* 45.9%, *P* = 0.023) and longer asthma duration (8.04 ± 6.61 *vs.* 5.72 ± 10.56 years, *P* \< 0.0001) compared to nonsevere asthmatics. They had higher prevalences of upper airway comorbidities such as chronic rhinosinusitis (50.0% *vs.* 35.0%, *P* = 0.008) and nasal polyps (41.7% *vs.* 28.0%, *P* = 0.007). However, no difference was noted in the proportion of female sex or atopy between severe and nonsevere asthmatics (62.55% *vs.* 61.87%, *P* = 0.848; 53.33% *vs.* 54.48%, *P* = 0.885, respectively). Severe asthmatics had lower levels of baseline forced expiratory volume in 1 second (FEV1; 71.38% ± 21.81% *vs.* 89.75% ± 20.29%, *P* \< 0.001) and lower methacholine PC20 levels (7.37 ± 12.15 *vs.* 10.79 ± 20.09 mg/mL, *P* = 0.042). While log-transformed serum total IgE level was not significantly different (2.27 ± 0.55 *vs.* 2.20 ± 0.64, *P* = 0.248), log-transformed TEC was measured higher in severe asthmatics (2.53 ± 0.44 *vs.* 2.39 ± 0.47, *P* = 0.002). Sputum eosinophil count was identified higher in severe asthmatics (26.95% ± 35.59% *vs.* 22.11% ± 33.15%, *P* = 0.031), whereas sputum neutrophil count was not different between the groups (56.62% ± 35.29% *vs.* 58.90% ± 33.84%, *P* = 0.558). Both serum ECP level (44.52 ± 45.95 µg/L *vs.* 31.99 ± 38.46 µg/L, *P* \< 0.0001) and serum periostin level (91.56 ± 41.21 ng/mL *vs.* 77.72 ± 38.56 ng/mL, *P* = 0.001) were measured higher in severe asthmatics than in nonsevere asthmatics.

###### Comparisons of clinical characteristics and eosinophil biomarkers between severe and nonsevere asthmatics

![](aair-11-394-i001)

  Variables                                    Severe asthmatics (n = 235)   Non severe asthmatics (n = 898)   *P* value
  -------------------------------------------- ----------------------------- --------------------------------- -----------
  Age (yr)                                     46.01 ± 13.93                 42.69 ± 14.63                     0.001
  Sex (female, %)                              62.6                          61.9                              0.848
  Atopy (%)                                    54.4                          54.9                              0.885
  Smoking history (current and ex-smoker, %)   57.4                          45.9                              0.023
  Duration of asthma (yr)                      8.04 ± 6.61                   5.72 ± 10.56                      \< 0.0001
  Chronic rhinosinusitis (%)                   50.0                          35.0                              0.008
  Nasal polyp (%)                              41.7                          28.0                              0.007
  Log (baseline FEV1)                          1.83 ± 0.15                   1.94 ± 0.12                       \< 0.0001
  Log (methacholine PC20)                      0.40 ± 0.67                   0.53 ± 0.73                       0.042
  Log (total IgE)                              2.27 ± 0.55                   2.20 ± 0.64                       0.248
  Log (total eosinophil count)                 2.53 ± 0.44                   2.39 ± 0.47                       0.002
  Sputum eosinophil (%)                        26.95 ± 35.59                 22.11 ± 33.15                     0.031
  Sputum neutrophil (%)                        56.62 ± 35.29                 58.90 ± 33.84                     0.558
  Serum ECP (µg/L)                             44.52 ± 45.95                 31.99 ± 38.46                     \< 0.0001
  Serum EDN (MBL) (ng/mL)                      69.08 ± 42.40                 58.46 ± 35.56                     0.034
  Serum EDN (K-EDN) (ng/mL)                    157.75 ± 128.18               109.02 ± 104.12                   0.001
  Serum periostin (ng/mL)                      91.56 ± 41.21                 77.72 ± 38.56                     0.001

Each value is presented as mean ± standard deviation or %.

FEV1, forced expiratory volume in 1 second; PC20, provocation concentration causing a 20% fall in FEV1; Log (total IgE), log-transformed serum total immunoglobulin E levels; Log (total eosinophil count), log-transformed total eosinophil count; ELISA, enzyme-linked immunosorbent assay; EDN, eosinophil-derived neurotoxin; Serum EDN (MBL), serum EDN levels measured by ELISA kit of MBL; Serum EDN (K-EDN), serum EDN levels measured by ELISA kit of K-EDN.

Comparison of serum EDN levels measured by the 2 different ELISA kits
---------------------------------------------------------------------

Serum EDN levels measured by both MBL and K-EDN kits were higher in severe asthmatics (69.08 ± 42.40 *vs.* 58.46 ± 35.56 ng/mL, *P* = 0.034; 157.75 ± 128.18 *vs.* 109.02 ± 104.12 ng/mL, *P* = 0.001, respectively), while no difference was found between nonsevere asthmatics and NCs (*P* = 0.55) as shown in [Fig. 1](#F1){ref-type="fig"}. Although a significant correlation was found between serum EDN levels measured by the 2 ELISA kits (*ρ* = 0.545; *P* \< 0.0001), the mean serum EDN level was found to be higher by the K-EDN kit than by the MBL kit in all study subjects. Serum EDN levels measured by the MBL kit showed a significant difference between severe and nonsevere asthmatics, but they were not so significant as serum EDN levels measured by the K-EDN kit (*P* = 0.034 and *P* = 0.001, respectively; [Fig. 1](#F1){ref-type="fig"}). The mean age of NCs was 51.1 years, which was older than that of severe or nonsevere asthmatics. Analysis of covariance was performed to identify the contribution of age to the serum EDN levels measured by the K-EDN kit, but no significant impact was observed (*P* = 0.104).

![(A) Comparison of serum EDN levels measured by the K-EDN kit among severe asthmatics, nonsevere asthmatics, and NCs. (B) Comparison of serum EDN levels measured by the MBL kit between severe asthmatics, nonsevere asthmatics, and NCs.\
EDN, eosinophil-derived neurotoxin; NC, normal control.](aair-11-394-g001){#F1}

Association of serum EDN with clinical parameters including TEC
---------------------------------------------------------------

When correlations between serum EDN levels measured by the 2 kits and TEC were evaluated, serum EDN levels measured by the K-EDN kit showed a higher correlation coefficient (*ρ* = 0.358, *P* \< 0.001, [Fig. 2A](#F2){ref-type="fig"}) than that measured by the MBL kit (*ρ* = 0.319, *P* \< 0.001, [Fig. 2B](#F2){ref-type="fig"}). Serum periostin levels were less correlated to TEC than serum EDN levels measured by the 2 kits (*ρ* = 0.222, *P* \< 0.0001, [Fig. 2C](#F2){ref-type="fig"}). Significant correlations were found between serum EDN levels measured by the 2 kits and serum periostin levels (*ρ* = 0.304, *P* \< 0.0001 for serum EDN levels measured by K-EDN kit; *ρ* = 0.302, *P* \< 0.0001 for serum EDN levels measured by MBL kit), but less correlated to TEC. Serum EDN levels measured by the 2 kits were significantly correlated (*ρ* = 0.545, *P* \< 0.0001). Serum ECP levels were correlated to TEC (*ρ* = 0.302, *P* \< 0.0001); they were less correlated to TEC than serum EDN levels were. There was no significant correlation between ECP levels and serum periostin levels (*ρ* = 0.083 and *P* = 0.083, respectively). Either serum ECP, EDN levels measured by the 2 kits or periostin levels were not correlated to sputum eosinophil count.

![Correlation between the eosinophilic biomarkers in total asthmatics. (A) TEC and serum EDN levels measured by the K-EDN kit. (B). TEC and serum EDN levels measured by the MBL kit. (C) TEC and serum periostin levels.\
EDN, eosinophil-derived neurotoxin; TEC, total eosinophil count.](aair-11-394-g002){#F2}

Serum EDN level as a biomarker of SA
------------------------------------

The receiver operating characteristic curves of serum EDN levels measured by the 2 kits were obtained to predict the phenotype of SA. Serum EDN levels measured by the K-EDN kit showed a higher area under the curve (AUC) value with statistical significance (AUC value: 0.632, *P* = 0.002 at the cutoff value of 85.97 ng/mL with 60.3% of sensitivity and 56.6% of specificity, [Fig. 3A](#F3){ref-type="fig"}) than those measured by the MBL kit (AUC value: 0.576, *P* = 0.034 at the cutoff value of 53.22 ng/mL with 60.7% of sensitivity and 56.2% of specificity, [Fig. 3B](#F3){ref-type="fig"}). In addition, the predictability of each clinical parameter for SA was analyzed using univariate and multivariate logistic regression analyses ([Table 2](#T2){ref-type="table"}). Serum EDN levels measured by both K-EDN and MBL kits as well as serum ECP and periostin levels were identified to be significant parameters associated with SA in the univariate analysis (all *P* \< 0.05). However, multivariate analysis showed that serum EDN levels measured by the K-EDN kit remained a significant parameter (*P* = 0.003) for predicting the phenotype of SA.

![(A) ROC curves for the serum EDN levels measured by the K-EDN kit in the prediction of severe asthma in the total asthmatics. (B) ROC curves for the serum EDN levels measured by the MBL kit in the prediction of severe asthma in the total asthmatics.\
ROC, receiver operating characteristic; EDN, eosinophil-derived neurotoxin; AUC, area under the curve; CI, confidence interval.](aair-11-394-g003){#F3}

###### Predictability for severe asthma by univariate and multivariate logistic regression analyses

![](aair-11-394-i002)

  Variable                       Univariate             Multivariate                          
  ------------------------------ ---------------------- -------------- ---------------------- -------
  Duration of asthma             1.016 (0.995--1.038)   0.131          \-                     \-
  Total IgE (IU/L)               1.000 (1.000--1.000)   0.694          \-                     \-
  Total eosinophil count (/uL)   1.000 (1.000--1.000)   0.116          \-                     \-
  Sputum eosinophil count (%)    1.004 (0.998--1.011)   0.207          \-                     \-
  Sputum neutrophil count (%)    0.998 (0.991--1.005)   0.586          \-                     \-
  Serum ECP (µg/L)               1.007 (1.002--1.011)   0.002          \-                     \-
  Serum periostin (ng/mL)        1.008 (1.003--1.013)   0.001          \-                     \-
  Serum EDN (MBL) (ng/mL)        1.007 (1.001--1.013)   0.025          \-                     \-
  Serum EDN (K-EDN) (ng/mL)      1.003 (1.001--1.006)   0.003          1.004 (1.002--1.007)   0.003

CI, confidence interval; IgE, immunoglobulin E; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; ELISA, enzyme-linked immunosorbent assay; Serum EDN (MBL), serum EDN levels measured by ELISA kit of MBL; Serum EDN (K-EDN), serum EDN levels measured by ELISA kit of K-EDN; OR, odds ratio.

The total study subjects were divided into 2 groups (high responders and low responders) according to each cutoff value of 85.97 ng/mL for the K-EDN kit and 54.22 ng/mL for the MBL kit; their demographic and clinical characteristics were compared (data not shown). The high-responders of the K-EDN showed a higher prevalence of SA (31.5% *vs.* 18.9%, *P* = 0.016) as well as a lower log-transformed baseline FEV1 level (1.92 ± 0.11 *vs.* 1.95 ± 1.00, *P* = 0.019) compared to low-responders of the K-EDN. They also had higher log-transformed TEC and sputum eosinophil count (2.58 ± 0.46 *vs.* 2.35 ± 0.41, *P* \< 0.0001; 28.59% ± 37.37% *vs.* 18.14% ± 31.79%, *P* = 0.044, respectively), and lower serum ECP (52.83 ± 46.30 µg/L *vs.* 31.65 ± 32.62 µg/L, *P* \< 0.0001) and periostin (95.88 ± 44.74 ng/mL *vs.* 73.63 ± 36.16 ng/mL, *P* \< 0.0001) levels; methacholine PC20 levels and sputum neutrophil counts had no differences (*P* = 0.813 and *P* = 0.960, respectively). The high-responder group of the MBL kit had similar results of higher SA prevalence (29.8% *vs.* 17.6%, *P* = 0.007), lower log-transformed baseline FEV1 level (1.92 ± 0.12 *vs.* 1.96 ± 0.09, *P* = 0.003), higher log-transformed TEC and sputum eosinophil count (2.58 ± 0.44 *vs.* 2.32 ± 0.45, *P* \< 0.0001; 28.75% ± 37.49% *vs.* 17.64% ± 30.83%, *P* = 0.025, respectively), as well as higher serum ECP and periostin level (47.97 ± 44.33 µg/L *vs.* 33.19 ± 37.38 µg/L, *P* \< 0.0001; 92.83 ± 40.59 ng/mL *vs.* 74.66 ± 39.49 ng/mL, *P* \< 0.0001, respectively). Additionally, they had a higher female proportion and a lower log-transformed methacholine PC20 level compared to low responders of MBL kit (55.6% *vs.* 68.4%, *P* = 0.012; 0.57 ± 0.63 *vs.* 0.77 ± 0.58, *P* = 0.009, respectively).

DISCUSSION
==========

Eosinophils are key cells in the airway inflammation of SA and associated with persistent elevation of type 2 inflammatory markers. Since increased expression of periostin in serum/tissue has been suggested to be a biomarker for type 2 inflammation in adult asthmatic patients,[@B20] our previous study demonstrated that adult asthmatics with SA had significantly higher serum periostin levels, indicating that serum periostin is a biomarker for type 2 inflammation in adult asthmatics.[@B4] However, the present study showed that the serum periostin level was not correlated with TEC, whereas TEC is a marker for determining anti-IL-5 antibody treatment for SA patients. It is necessary to establish a useful serum biomarker for assessing the degree of type-2 airway inflammation in the management of SA.[@B21][@B22] There have been a few studies suggesting the serum EDN level to be a biomarker for asthma severity in childhood.[@B23] This is the first study to suggest that the serum EDN level is a useful serum biomarker for assessing the severity of SA in adult asthmatics. The serum EDN level was significantly higher in patients with SA than in those with NSA; the significant correlation coefficient was noted between TEC and serum EDN measured by the K-EDN kit compared to those by the MBL kit, and between TEC and serum periostin/ECP levels. In addition, multivariate analysis showed that serum EDN levels measured by the K-EDN kit remained a single significant parameter for predicting SA.

Recent large-scale studies have led to a better understanding of the characteristics of SA. They proved distinct demographic/clinical characteristics consistently relevant to SA; older age, possible associations with female sex and smoking, frequent exacerbations, low baseline lung function, atopy rate, need for high doses of inhaled or systemic CS, and higher prevalence of upper and lower respiratory comorbidities.[@B24][@B25][@B26] We confirmed that the characteristics of severe asthmatics in this study were consistent with these findings. However, no differences were noted in the female sex and atopy. It also showed that lower lung function and increased AHR are key features of SA. Moreover, it was noted that eosinophilic inflammation was another key feature of SA in this study. Serum EDN levels measured by the K-EDN and MBL kits as well as TEC, sputum eosinophil count, serum periostin, and serum ECP levels were significantly higher in severe asthmatics than in nonsevere asthmatics. These findings confirmed that eosinophilia in blood/airway secretion is the key feature of SA in adult asthmatics. TEC and sputum eosinophilia (\>3%) have been used to define eosinophilic asthma.[@B27][@B28][@B29] A previous study demonstrated that adult asthmatics with more than 300/µL of TEC had the highest tendency of asthma exacerbation among cutoff values of 200 to 400/µL.[@B30] Still, another study demonstrated that TEC was rarely correlated with eosinophilia in bronchoalveolar lavage (BAL) fluid or endobronchial biopsies in patients with SA.[@B31] It is not practical to differentiate phenotypes using these parameters, since the phenotypes vary widely among patients and depend on clinical severity and medications used.[@B26][@B32][@B33] Due to these clinical characteristics of SA, clinically applicable serum biomarkers that reflect eosinophilic inflammation are necessary to keep severe asthmatics from exacerbation and lung function decline.

It is essential to distinguish phenotypes between eosinophilic and noneosinophilic asthmatics because the more severe eosinophilic inflammation, the higher risk of asthma exacerbation which develops SA. Effective control of eosinophilic inflammation has proved beneficial to reduce asthma exacerbation.[@B34][@B35][@B36][@B37] As the phenotype of eosinophilic asthma has been determined by sputum eosinophil counts, sputum induction carries a risk of asthma exacerbation, especially in severe asthmatics, and it is not always successful because of its variability.[@B38] In addition, lab facilities and expertise are required to analyze sputum samples. For this reason, a serum biomarker, which is stable and reproducible to represent type 2 inflammation, is considered useful as it is relatively safe and easy-to-access in real clinical practice. Among eosinophil-derived molecules, EDN is known to be relatively cheap and stable to measure. Elevated EDN levels were found in serum, urine, and other body fluids in patients with eosinophil-associated diseases.[@B39] The serum EDN level was the only marker for differentiating childhood asthmatics with acute exacerbation from those in stable status, showing a greater correlation with the severity of asthma when compared to serum ECP levels or TEC.[@B23] In addition, it was correlated with the degree of persistent airflow limitation in allergic asthmatics.[@B40] Our previous study investigated that peripheral blood eosinophils and serum EDN levels were elevated in SA, which was attributed to increased eosinophil extracellular traps that promoted the degranulation of eosinophils. A significnat correlation was found between extracellular trap-contating eosinophils and EDN levels.[@B41] We found that the serum EDN level was significantly higher in severe asthmatics than in nonsevere asthmatics; especially, serum EDN level measured by the K-EDN kit are more significantly elevated in severe asthmatics than those measured by the MBL kit. We also observed that serum EDN levels measured by the K-EDN kit was significantly elevated in severe asthmatics compared to NCs, while no difference was found between nonsevere asthmatics and NCs or between total asthmatics and NCs. Additionally, serum EDN levels measured by the K-EDN kit showed a better correlation to TEC than those measured by the MBL kit or serum periostin levels. Moreover, serum EDN levels measured by the K-EDN kit could predict SA best among other clinical parameters. Periostin is known as a type 2 inflammation marker, but it is mainly released from airway epithelial cells affected by IL-13 and various stimuli, but not from eosinophils. In the present study, a relatively weak correlation was found between the serum periostin and TEC levels. In patients with SA, furthermore, periostin is more valuable in evaluating eosinophil activation status than in evaluating peripheral eosinophil count. When eosinophils are activated, they release several mediators including MBP, ECP, and EDN. To date, we cannot measure serum MBP levels using a kit. Several studies showed confounding results of serum ECP level as a biomarker for asthma and other allergic diseases.[@B15][@B42][@B43] Serum ECP level can be measured using commercially available kits, although their cost is expensive. In the present study, a significantly higher serum ECP level was noted in severe asthmatics than in nonsevere asthmatics; however, a lower correlation was found with TEC. ECP is also a highly charged protein with sticky quality; therefore, it is likely to adhere to the wall of a sample tube or other substances. Therefore, its level is variable from each measurement. These findings suggest that the serum EDN level can be applied as a stable serum biomarker for better assessing the severity of eosinophilic inflammation, especially in SA.

There are several limitations in this study. First, it is a cross-sectional study in a single tertiary center. Although the number of subjects was not small, replicated experiments in other subjects\' samples are needed to enhance and consolidate the hypothesis. Secondly, it was difficult to control the medications such as inhaled/systemic CS that could affect eosinophilic inflammation status in the study subjects. Thirdly, further investigations are required to explore the exact function of EDN (difference from periostin) and other inflammatory mechanisms than eosinophilic inflammation in the pathogenesis of SA. Airway neutrophilia was documented in patients with severe exacerbations, but its role in SA remains to be elucidated.[@B44] A few studies demonstrated increased IL-17 levels in samples (induced sputum, BAL samples, and bronchial biopsies) of severe asthmatics.[@B45][@B46][@B47] In another study, IL-17-producing cells and IL-17-related gene expression signature were increased and orthogonal to eosinophilic inflammation in SA.[@B48] Some patients with SA have mixed cellular profiles (both sputum eosinophilia and neutrophilia). Our previous report demonstrated increased expression of neutrophil extracellular traps (NETs) in severe asthmatics compared to nonsevere asthmatics. NETs were found to induce eosinophil activation, suggesting a close interaction between these 2 inflammatory cells.[@B49] Follow-up studies are essential to evaluate the clinical significance of serum EDN, treatment response to anti-inflammatory medications, and long-term outcomes in SA.

The results of this study suggest that the serum EDN level can help identify SA in adult asthmatics. Considering that SA has heterogeneous phenotypes, further studies are needed to identify useful biomarkers for assessing subtypes and long-term clinical outcome of SA.
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